Valeant Pharmaceuticals Rating Lowered To 'B+', Still On Watch Negative - S&P Global Ratings’ Credit Research

Valeant Pharmaceuticals Rating Lowered To 'B+', Still On Watch Negative

Valeant Pharmaceuticals Rating Lowered To 'B+', Still On Watch Negative - S&P Global Ratings’ Credit Research
Valeant Pharmaceuticals Rating Lowered To 'B+', Still On Watch Negative
Published Nov 16, 2006
576 words — Published Nov 16, 2006
Price US$ 150.00  |  Buy this Report Now

About This Report

  
Abstract:

NEW YORK (Standard&Poor's) Nov. 16, 2006--Standard&Poor's Ratings Services today lowered its ratings on Costa Mesa, Calif.-based Valeant Pharmaceuticals International. The corporate credit rating was lowered to 'B+' from 'BB-'. The ratings remain on CreditWatch with negative implications, where they were placed Oct. 24, 2006 to reflect the ongoing uncertainty regarding the company's inability to file its Form 10-Q for the third quarter and the consequences if the company is not able to resolve the situation in 60 days. "The ratings downgrade reflects our concern regarding specialty pharmaceutical company Valeant's continued struggles to generate earnings and cash flow growth," explained Standard&Poor's credit analyst Arthur Wong. Sales growth of the company's core product portfolio has been

  
Brief Excerpt:

RESEARCH Valeant Pharmaceuticals Rating Lowered To 'B+', Still On Watch Negative Publication date: 16-Nov-2006 NEW YORK (Standard & Poor's) Nov. 16, 2006--Standard & Poor's Ratings Services today lowered its ratings on Costa Mesa, Calif.-based...

  
Report Type:

Ratings Action

Ticker
VRX
Issuer
Bausch Health Companies Inc.
GICS
Pharmaceuticals (35202010)
Sector
Global Issuers
Country
Canada
Region
Canada
Format:
HTML HTML
Buy Now

More from S&P Global Ratings’ Credit Research

S&P Global Ratings’ Credit Research—S&P Global Ratings’ credit research provides analysis on issuers and debt obligations of corporations, states and municipalities, financial institutions, insurance companies and sovereign governments. S&P Global Ratings also offers insight into the credit risk of structured finance deals, providing an independent view of credit risk associated with a growing array of debt-securitized instruments.

About the Author


Cite this Report

  
MLA:
S&P Global Ratings’ Credit Research. "Valeant Pharmaceuticals Rating Lowered To 'B+', Still On Watch Negative" Nov 16, 2006. Alacra Store. May 25, 2025. <http://www.alacrastore.com/s-and-p-credit-research/Valeant-Pharmaceuticals-Rating-Lowered-To-B-Still-On-Watch-Negative-545931>
  
APA:
S&P Global Ratings’ Credit Research. (). Valeant Pharmaceuticals Rating Lowered To 'B+', Still On Watch Negative Nov 16, 2006. New York, NY: Alacra Store. Retrieved May 25, 2025 from <http://www.alacrastore.com/s-and-p-credit-research/Valeant-Pharmaceuticals-Rating-Lowered-To-B-Still-On-Watch-Negative-545931>
  
US$ 150.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.